Syndesi Therapeutics SA
Syndesi Therapeutics reported total assets of 607,532 € at the end of the 2025 financial year (annual accounts filed with the NBB on 08 Jun 2026).
By total assets for 2025, Syndesi Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year. Largest companies in the sector →
The score of Syndesi Therapeutics shows with a free account.
See the score- Summary? / 5
- Balance sheet strength
- Liquidity
- Repayment capacity
- Profitability
- Trajectory
- Compliance and register
- Position in its sectorvs peers
- Supplier creditat 30 d
- Borrowing capacityborrowable
- Valuationcentral
Visible once signed in: create your account, the 14-day Pro trial is free.
Key figures 2025
Change 2023 → 2025: Total assets -11 %
Accounts of the company itself (not consolidated).
The full file covers 7 financial years; a free account shows 2. →Deterministic calculation on the filed accounts, no AI. Dispute the score or report an error
Syndesi Therapeutics's annual accounts
Filed annual accounts
- Year ended 31 Dec 2025filed on 08 Jun 2026
- Year ended 31 Dec 2024filed on 17 Jun 2025
- Year ended 31 Dec 2023filed on 22 Jul 2024
- Year ended 31 Dec 2022filed on 12 Oct 2023
- Year ended 31 Dec 2021filed on 25 Jul 2022
Syndesi Therapeutics's financial analysis
- Solvency-21385.2%sector median: 57.9%
- Current ratio
- Net margin
- ROE
- Financial debt / EBITDA
- Interest coverage
- Days sales outstanding (DSO)
Management and control of Syndesi Therapeutics
Syndesi Therapeutics's publications in the Belgian Gazette
Company number, VAT number and registered office
- Company number (CBE)
- 0686.599.355
- VAT number
- BE0686599355
- Peppol
- Registered · 0208:0686599355 · as of 10 Nov 2026
- Legal form
- SA
- Incorporated
- 19 Dec 2017
- Registered office
- 1300 Wavre
- Latest accounts
- 2025 · filed on 08 Jun 2026
- Activity
- Research and experimental development on biotechnology (NACE 72101)
Syndesi Therapeutics (SA) has been based in Wavre since 2017, active in: research and experimental development on biotechnology. For 2025, it reports a net loss of €12.0m and equity of −€129.9m; its revenue is not published. Its solvency stands at -21385.2%, below the median of its sector (57.9%).
Guide: Reading Belgian SME accounts: the five figures that count →
Companies similar to Syndesi Therapeutics
Companies in the same business, of comparable size and area, outside its group.
- CABINET MEDICAL Geneviève MAHIEU Research and experimental development on natural sciences and engineering Dinant · balance sheet 536,793 €
- Exo-Harvest Research and experimental development on natural sciences and engineering Charleroi · balance sheet 764,057 €
- Taag Venture Capital Europe Research and experimental development on natural sciences and engineering Antwerp · balance sheet 845,167 €
- E-Biom Research and experimental development on natural sciences and engineering Gembloux · balance sheet 372,985 €
- Dokter Bart Gordts Research and experimental development on natural sciences and engineering Bruges · balance sheet €1.19m
- Global Mobile Lab Research and experimental development on natural sciences and engineering Saint-Hubert · balance sheet €1.26m
- Dr. D. FRANCOIS PHOTOMED Research and experimental development on natural sciences and engineering Molenbeek-Saint-Jean · balance sheet 291,936 €
- Europe Inland Logistics Solar 21 Research and experimental development on natural sciences and engineering Herentals · balance sheet €1.33m
Frequently asked questions about Syndesi Therapeutics
What is the revenue of Syndesi Therapeutics?
Syndesi Therapeutics files its accounts in a format where revenue is optional: it is not published for 2025.
What is the VAT number of Syndesi Therapeutics?
In Belgium, the VAT number is the company number prefixed with BE: BE0686599355 for Syndesi Therapeutics, if the company is VAT-registered. Its company number (CBE) is 0686.599.355.
Where is the registered office of Syndesi Therapeutics?
According to the CBE register, the registered office of Syndesi Therapeutics is in 1300 Wavre.
What is the equity of Syndesi Therapeutics?
At the close of the 2025 financial year, the equity of Syndesi Therapeutics amounts to -129,921,795 €, a solvency of -21385.2% of total assets.
Who manages Syndesi Therapeutics?
The register lists 2 active mandates at Syndesi Therapeutics. Names and roles are in the full file, with the deeds published in the Belgian Gazette.
How large is Syndesi Therapeutics within its sector?
By total assets for 2025, Syndesi Therapeutics ranks in the top half of the 993 companies in its sector (NACE 7210) in Belgium that filed accounts for that financial year.
The full file of Syndesi Therapeutics
Directors and mandates, ownership network, Gazette deeds, ten years of accounts and ratios, Excel export, and Idonis's analysis in one question.
Open the full file →